H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $20.00 price target on Actuate Therapeutics (NASDAQ: ACTU).

The analyst commented: "Last week, Actuate presented a clinical data update from the ongoing randomized Phase 2 Study 1801, Part 3B at the 2026 annual symposium of ASCO-GI. The study evaluated a combination of elraglusib and gemcitabine/nab-paclitaxel (GnP) vs GnP alone in 1L metastatic pancreatic ductal adenocarcinoma (mPDAC). The elraglusib combination arm achieved a statistically significant median overall survival (mOS) of 10.1 months vs 7.2 months in GnP alone (HR=0.62; p=0.02), a 38% reduction in the risk of death (Exhibit 1). Additionally, the combination cohort achieved a statistically significant 12-month survival rate of 44.4% roughly double to that achieved by the GnP arm of 22.3% (p=0.0004). Durability improved in the combination arm of elraglusib and GnP arm with an 18-month OS of 22.9% (vs 6.6% by GnP cohort) and 24-month OS of 12.9% (vs 2.6% by GnP arm). While serious TEAEs were comparable between groups (~56%), the elraglusib arm experienced a notably higher rate of Grade 3+ neutropenia (53.5% vs. 32.1%) – although there was no difference in the rates of sepsis in the Grade 3+ neutropenia patients. Looking ahead, the company plans to discuss Phase 2 data with the regulatory agency in 1H26, and we believe a Phase 3 study could be initiated by YE26. Furthermore, the company identified 4 specific genomic mutations (i.e., TP53, KRAS, CDKN2A, and ARID1A) that could be negative predictive biomarkers specifically within the elraglusib arm, which management may be able to utilize to inform the design of the Phase 3 study to optimize its probability of success."

For an analyst ratings summary and ratings history on Actuate Therapeutics click here. For more ratings news on Actuate Therapeutics click here.

Shares of Actuate Therapeutics closed at $5.26 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• AeroVironment wins $117M Army drone contract
• FG Merger II sets stockholder vote on BOXABL merger for June 9